Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 3/20 | 0.51 |
| ▸ | PDCD1LG2 | Q9BQ51 | 1/20 | 0.34 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.34 |
| ▸ | ENPEP | Q07075 | 2/20 | 0.32 |
| ▸ | FAP | Q12884 | 1/20 | 0.32 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.32 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.32 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2194506 | 0.86 | ALDH1A1 (0.42) | DPP4PDCD1LG2CD274ENPEP | |
| SCHEMBL30811203 | 0.85 | DPP4 (0.51) | DPP4PDCD1LG2CD274ENPEP | |
| SCHEMBL26263797 | 0.80 | DPP4 (0.47) | DPP4PDCD1LG2CD274ENPEPFAP | |
| SCHEMBL30684497 | 0.80 | DPP4 (0.47) | DPP4PDCD1LG2CD274ENPEPFAP | |
| SCHEMBL32690486 | 0.79 | ENPEP (0.44) | DPP4ENPEP | |
| SCHEMBL27299206 | 0.79 | PDCD1LG2 (0.33) | DPP4PDCD1LG2CD274ENPEPFAP | |
| SCHEMBL31074245 | 0.78 | DPP4 (0.45) | DPP4PDCD1LG2CD274 | |
| SCHEMBL26781562 | 0.78 | PDCD1LG2 (0.35) | DPP4PDCD1LG2CD274ENPEP | |
| SCHEMBL4127016 | 0.76 | DPP4 (0.62) | DPP4FAPDPP8DPP9DPP7 | |
| SCHEMBL25650702 | 0.74 | DPP4 (0.51) | DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260083865-A1 | PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) LIGANDS AND USE THEREOF | 3B PHARMACEUTICALS GMBH (DE) | 2026-03-26 | — | — | US | disclosed |
| CN-119923279-A | Prostate Specific Membrane Antigen (PSMA) ligands and uses thereof | 3B制药有限公司 | 2025-05-02 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260083865-A1 | PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) LIGANDS AND USE THEREOF | KLK3, FOLH1, PSMA1 | DPP4 720/4885PDCD1LG2 1069/4885CD274 1006/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.